Progress Report: Sri Lanka Clinical Trials Registry

SLCTR regist	tration number: SLC	TR/2015/002		
				nase 3 Study to Evaluate mic Lupus Erythematosus
Date of com	mencement (enrolm	ent of first participant):	09 April 2015. Gl	obal – 04 April 2013
Progression:	6 months□	I year □	2 years □	3 years □
	At completion x			
I. Baseline	e data			
	nencement date - 4th	April 2013 Lanka – 9 April 2015		
		nethodology/ protocol a ocol amendment sheet o		
Any changes	to trial outcomes af	ter commencement: Ye	s, SRI-8 to SRI-6	
2. Current	t status			
Recruitment	status: recruitment :	suspended		
Number asse Globally- 588 In Sri Lanka -				
				
Globally - 44	uited and randomize 2	ed:		
In Sri Lanka -	01			
Number alloo provided.	cated to each interve	ention/arm: Study is blir	nded so this inforr	nation cannot be
	sions after randomiza	ation:		
Globally – 82 In Sri Lanka –				
ii Jii Laiika -	- 0			
3. Trial ou	tput			

or real suspec

Summary of Interim/Final data (if available):

Completion of an interim analysis of its Phase 3 trial (CHABLIS-SCI) of blisibimod in patients with Systemic Lupus Erythematosus took place in February 2015. The outcome was that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SCI study, evaluating the SRI-6 response at the 24 week time point

Presentations of results at scientific meetings: No presentations of results have occurred during the reporting period.

Publications: No publications relevant to blisibimod have been published during the reporting period.

Dr Lalith Wijayaratne

Consultant Rheumatologist

National Hospital of Sri Lanka JAVARATNE

Dr. LAUTON MD FRCP (Lond) MBBS, MD, FRCP (Lond) CONS. PHYSICIAN IN CHARGE DEPARTMENT OF RHEUMATOLOGY & MEDICAL REHABILITATION (G) THE NATIONAL HOSPITAL, COLOMBO Date: 16.02.2017